Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery

Trial Profile

Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Nepafenac (Primary)
  • Indications Retinal oedema
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 27 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Jan 2015 Planned End Date changed from 1 Jun 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 27 Jan 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top